echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Infection > Novavax has started Phase III clinical trials of the COVID-19 candidate vaccine NVX-CoV2373 in the UK.

    Novavax has started Phase III clinical trials of the COVID-19 candidate vaccine NVX-CoV2373 in the UK.

    • Last Update: 2020-10-11
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Novavax recently said it has launched its first Phase III clinical trial to assess the efficacy, safety and immunogenicity of its COVID-19 vaccine candidate NVX-CoV2373.
    trial is being carried out in the UK and 10,000 participants aged between 18 and 84 are expected to be recruited over the next four to six weeks.
    Gregory Glenn, head of research and development at Novavax, commented: "We are optimistic that high levels of SARS-CoV-2 transmission will continue in the UK and we are optimistic about this critical Phase III clinical trial."
    of the study will support regulatory licensing applications in the EU and other countries.
    50 percent of the participants will receive two doses, including 5 mcg of protein antigens and 50 mcg of Matrix-M advents, 21 days apart, and the other half will be given a placebo.
    , according to Novavax, the trial aims to recruit at least 25 percent of participants over the age of 65 and give priority to those most affected by COVID-19.
    , as many as 400 people will be vaccinated against seasonal influenza as part of the study to assess the potential benefits of co-medication.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.